CLAIMS

1. A pharmaceutical composition, wherein the composition is an aqueous liquid solution comprising:

20-200 mg/ml anti-TGFβ antibody, wherein the antibody comprises a heavy chain variable domain (V_H) amino acid sequence corresponding to residues 1-120 of SEQ ID NO:1 and a light chain variable domain (V_L) amino acid sequence corresponding to residues 1-108 of SEQ ID NO:2,

10-50 mM acetate, optionally 25 mM acetate, and

5-15% w/v sucrose, optionally 8% w/v sucrose,

wherein the solution has a pH of 5.0 ± 0.2 or 5.0 ± 0.3.

2. The composition of claim 1, wherein the antibody comprises a heavy chain amino acid sequence set forth in SEQ ID NO:1 (with or without the C-terminal lysine) and a light chain amino acid sequence set forth in SEQ ID NO:2.

3. The composition of claim 1 or 2, further comprising a surfactant.

4. The composition of claim 3, wherein the surfactant is polysorbate, optionally polysorbate 80 (PS80).

5. The composition of claim 4, wherein PS80 is at a concentration of 0.01-0.10% w/v, optionally 0.06% w/v.

6. The composition of any one of the preceding claims, wherein the anti-TGFβ antibody is at a concentration of 40-180 mg/ml, optionally 50 mg/ml or 150 mg/ml.

7. The composition of any one of the preceding claims, further comprising a chelating agent, optionally selected from EDTA and DPTA.

8. The composition of claim 7, wherein the chelating agent is at a concentration of 0 to 20 μM, optionally 10 μM.

9. The composition of any one of the preceding claims, wherein the aqueous liquid solution has a pH of 4.7-5.3.

10. The composition of claim 1, comprising:

50 mg/ml, 75 mg/ml, or 150 mg/ml anti-TGFβ antibody,

25 mM acetate,

10 μM EDTA,

0.06% PS80, and

8% w/v sucrose,
with a pH of 5.0 $\pm$ 0.3.

11. The composition of claim 10, wherein the antibody comprises a heavy chain amino acid sequence set forth in SEQ ID NO:1 and a light chain amino acid sequence set forth in SEQ ID NO:2.

12. An article of manufacture, comprising a vial and instructions for use, wherein the vial contains about 16 ml of the composition of claim 11.

13. Use of the composition of any one of claims 1-11 in the manufacture of a medicament for treating cancer in a patient in need thereof.

14. The use of claim 13, wherein an additional anti-cancer therapeutic is to be administered.

15. The use of claim 13 or 14, wherein the composition is to be administered intravenously at a dose of 5 mg/kg or 15 mg/kg, optionally biweekly.